T. Rowe Price Associates
IKT icon

T. Rowe Price Associates’s Inhibikase Therapeutics IKT Stock Holding History

T. Rowe Price Associates’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$203K Buy
99,632
+48,758
+96% +$87.3K ﹤0.01% 3001
2026
Q1 		$86K Buy
50,874
+20,268
+66% +$36K ﹤0.01% 3024
2025
Q4 		$63K Hold
30,606
– – ﹤0.01% 3010
2025
Q3 		$50K Hold
30,606
– – ﹤0.01% 3014
2025
Q2 		$60K Buy
+30,606
New +$59.9K ﹤0.01% 2983

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates's IKT Position: Q2 2026 in Review

T. Rowe Price Associates increased its Inhibikase Therapeutics (IKT) stake by 96% in Q2 2026, buying an estimated $87.3K and bringing the position to 99,632 shares worth $203K. The position accounts for ﹤0.01% of the portfolio, ranked #3001.

T. Rowe Price Associates first reported a position in IKT in Q2 2025 and has held it in 5 quarters since. 105 funds tracked by Wall St. Rank hold IKT as of Q2 2026.

  • T. Rowe Price Associates held 99,632 shares of Inhibikase Therapeutics worth $203K as of Q2 2026.
  • T. Rowe Price Associates bought 48,758 Inhibikase Therapeutics shares in Q2 2026, an estimated $87.3K.
  • Inhibikase Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #3001 holding.
  • T. Rowe Price Associates first reported a position in Inhibikase Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 105 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.